ALK is investing approximately DKK 500 million to expand its long-term manufacturing partnership with Catalent and increase capacity for fast-dissolving allergy immunotherapy tablets.

Sanofi and Cheplapharm have agreed a major mature-medicines transaction covering 20 products and three manufacturing sites in France, Hungary and Singapore.

CordenPharma is investing €80 million to expand aseptic fill-finish operations at its Caponago site in Italy, increasing projected sterile injectable capacity to up to 500 million units annually.

ADCAN Pharma and Pinnacle Life Science have entered into a licensing and technology-transfer partnership covering 12 oncology products and their planned local manufacture in the UAE.

BeOne Medicines has reached a voluntary agreement with the US government covering cancer medicine access, future pricing and continued investment in US pharmaceutical manufacturing.

BMS concluded that Cellares’ automated Cell Shuttle platform could not meet the specific requirements for commercial Breyanzi production, prompting Cellares to cut around 100 positions.

The commercial partnership combines 4basebio’s cell-free hpDNA platform with Genezen’s viral vector CDMO capabilities to provide cell and gene therapy developers with an alternative to conventional plasmid DNA manufacturing.

The acquisition adds SimoTech’s automation engineering and digital manufacturing expertise to Project Farma’s existing life sciences manufacturing services, creating a broader offering spanning facility strategy through GMP operations.

The proposed acquisition gives Wise Equity control of a specialist oral solid-dose manufacturer with established capabilities in effervescent, soluble, orally disintegrating and sublingual formulations.